Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03552731
Other study ID # RUMCPSY-ONC
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 20, 2017
Est. completion date December 20, 2025

Study information

Verified date March 2023
Source Richmond University Medical Center
Contact Dennis Bloomfield, MD
Phone 718-818-2707
Email dbloomfield@rumcsi.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study will examine the existence and severity of depression and anxiety in patients undergoing chemotherapy at RUMC. Patients currently undergoing initial chemotherapy cycle will be compared to patients undergoing a subsequent chemotherapy cycle. Data will then be collected using standardized depression and anxiety scales to assess if these comorbidities exist and to what severity level. Data already collected for depression and anxiety in patients with chronic, but not cancer, illness will be used as a control. The participants will be screened for signs of psychological distress using three self administered questionnaires: the Generalized Anxiety Disorder 7 item Scale (GAD7) and Patient Health Questionnaire (PHQ9). Demographic information about the participants, including medical and psychiatric history, will also be gathered from their medical records.


Description:

The purpose of the study is to see how common Anxiety, Depression and distress are in people who are undergoing treatment for cancer. We want to understand how common these issues are in order to better screen for, and treat people suffering from them. Past studies have shown that people with anxiety or depression and cancer have worse outcomes, and a study evaluating how common these issues are has not been done. Patients presenting for chemotherapy will be identified and approached for participation by members of the research team. The purpose and design of the study will be explained. After informed consent is obtained, the surveys will be administered by the study team. Completing surveys will take 20 minuets. Relevant demographic information will be collected from the patients EMR. Recruitment will extend over one year period. Those determined to be suffering from anxiety or depression will be given the option of psychiatric follow up or intervention.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 20, 2025
Est. primary completion date December 20, 2024
Accepts healthy volunteers
Gender All
Age group 18 Years to 89 Years
Eligibility Inclusion Criteria:1)Patients (greater than equal to) 18 years of age 2)Patients with a confirmed diagnosis of a solid tumor or hematologic cancer 3)Patients who are able to understand the informed consent and read the selfadministered metrics. 4)Patients undergoing chemotherapy. - Exclusion Criteria: - Patients unable to give informed consent. - Patients with a previous diagnosis of anxiety or depression prior to chemotherapy

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Surveys
GAD 7 Survey and PHQ 9 Interventional survey will be administered in both groups.

Locations

Country Name City State
United States Richmond University Medical Center Staten Island New York
United States Richmond University Medical Center Staten Island New York
United States Richmond University Medical Center Staten Island New York

Sponsors (1)

Lead Sponsor Collaborator
Richmond University Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Demographic Information To gather demographic information with a Demographic Survey Two years
Primary Generalized Anxiety Disorder Screener (GAD-7) Generalized Anxiety Disorder 7 (GAD-7) is a self-reported questionnaire for screening and severity measuring of generalized anxiety disorder (GAD). GAD-7 consists total score for the seven items ranges from 0 to 21. Scores of 5, 10, and 15 represent cut points for mild, moderate, and severe anxiety, respectively. Using the threshold score of 10, the GAD-7 has a sensitivity of 89% and a specificity of 82% for generalized anxiety disorder. Two years
Secondary Patient Heath Questionnaire-9 (PHQ-9) The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression: The PHQ-9 incorporates DSM-IV depression diagnostic criteria with other leading major depressive symptoms into a brief self-report tool.Depression Severity: 0- none, 1-4 minimal, 5-9 mild, 10-14 moderate, 15-19 moderately severe, 20-27 severe. Validity has been assessed against an independent structured mental health professional (MHP) interview. PHQ-9 score =10 had a sensitivity of 88% and a specificity of 88% for major depression. Two years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06022666 - PATH Program for for Severely Frail or Cognitively Impaired Patients Scheduled for Cancer Surgery. N/A
Completed NCT03664947 - The Impact of Exercise Approaches on Sleep in Children With Acute Lymphoblastic Leukemia N/A
Recruiting NCT05443321 - Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient Outcomes N/A
Completed NCT01772511 - Do Patients Participating In Oncology Clinical Trials Understand the Informed Consent Form? N/A
Completed NCT02708381 - Pilot Testing of a Real-Time Oncogeriatric Teleconsultation System Using the Total Cancer Careā„¢ Database
Completed NCT04213157 - Laparoscopic Partial Nephrectomy for cT1 Tumors
Completed NCT02329808 - Clinical Validation of a Dried Blood Spot Method for Analysis of Immunosuppressives and Antifungals in Pediatrics
Available NCT03412539 - Mechanism of Effectiveness of Neurosurgery Treatments for Durable Pain N/A